Allan C. Silber is the Chairman of Point Biopharma. He is also chairman of Verity Pharmaceuticals, a specialty pharmaceutical company and also chairs Heritage Global Inc., a global financial services and asset trading company providing corporate and financial asset monetization, advisory, and valuation services. Mr. Silber has an extensive background in the private equity, real-estate and financial services fields. Mr. Silber is the former CEO of Street Capital Group Inc. and Counsel Corporation
Jonathan Ross Goodman
Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB),which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Knight Therapeutics Inc.(TSE:GUD). Mr. Goodman is a recipient of the Globe and Mail’s Top 40 Under 40 award, Federation CJA’s Sam Steinberg Award for entrepreneurial excellence and Koach Award for leading campaigner, UIA Federations of Canada National Young Leadership Award of Distinction, the Special Recognition Award by Brain Injury Canada, Bernard Gross Leadership Award by ORT Montreal, was appointed Honorary Chairman of the Ride to Conquer Cancer and was named Quebec Entrepreneur of the Year in the Life Sciences by the National Post and Ernst & Young.
Peggy Gilmour is a senior finance, risk management and audit executive with a deep understanding of both US and Canadian regulatory environments. Most recently, Ms. Gilmour was Board Chair of the Institute of Internal Auditors, Toronto Chapter, and has previously held board, audit, governance & risk roles with organizations such as Metrolinx, Interac and Ontario Pension Board. A chartered accountant by training, Ms. Gilmour gained her extensive finance experience as CFO of the Operations & Technology Division within BMO Financial Group and as SVP of Finance at Aviva Insurance Canada.
Gerry Hogue is the founder of VieCure, an oncology EMR software platform, and presently serves as its President & CEO. Mr. Hogue has spent many years working in the field of enabling technologies for cancer care. In 1993, Mr. Hogue founded OpTx Corporation, which created the world’s first oncology-specific electronic medical record and decision support system.
Dr. Rajesh K. Malik, M.D.
Dr. Raj Malik, M.D. is the Chief Medical Officer of G1 Therapeutics. Previously, he served as Chief Medical Officer and management board member at Agennix AG, where he was responsible for research and development. Prior to Agennix AG, he served as Chief Medical Officer at Adherex Technologies, where he directed the company’s global regulatory strategy and clinical development programs. Dr. Malik also served in oncology clinical development positions at EMD Pharmaceuticals and Bristol-Myers Squibb. Dr. Malik currently serves on the board of directors of Meryx, Inc.
Dr. Malik received his M.D. from the University of Sheffield Medical School in the UK. He completed his residency at Duke University Medical Center and fellowships at the Children’s Hospital of Philadelphia and Duke University Medical Center. During his academic career, he was an assistant professor at the University of Virginia, where he conducted basic science and clinical research in addition to patient care and teaching.
Dr. Yael Margolin, Ph.D.
Dr. Yael Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. From 2005 to 2019, Dr. Margolin served as President, Chief Executive Officer and director of Gamida Cell Ltd. (Nasdaq: GMDA), a clinical stage biopharmaceutical company, leading the company from preclinical development through phase 3 international registration studies. Prior to that, Dr. Margolin was Vice President of Denali Ventures LLC, a venture capital firm focused on healthcare, and a program manager at Teva Pharmaceuticals. Dr. Margolin holds a BSc in biology and a MSc Cum Laude from the department of microbiology, both from Tel Aviv University in Israel, a Ph.D. from the department of membrane research at the Weitzman Institute of Science in Rehovot, Israel and was a post-doctoral associate at the Yale University School of Medicine.
David C. Lubner
David Lubner is a senior finance executive with more than 25 years of experience in the life sciences industry. Mr. Lubner most recently served as Executive Vice President and Chief Financial Officer of Ra Pharma, which was acquired by UCB in April 2020. Before joining Ra Pharma, he served as Chief Financial Officer of Tetraphase Pharmaceuticals, Inc. a biotechnology company, from its inception in 2006 to 2016, as Chief Financial Officer of and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company from 1999 until it was acquired by IMS Health in 2005 and as Vice President and Chief Financial Officer of and at ProScript, where Velcade® (bortezomib), a therapy widely used for the treatment of multiple myeloma, was discovered.
Mr. Lubner currently serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), a company developing life-transforming therapies for patients with serious muscle diseases, Gemini Therapeutics, Inc.,(Nasdaq: GMTX) a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration, Vor Biopharma, Inc. (Nasdaq: VOR) a cell therapy company combining a novel patient engineering approach with targeted therapies to treat patients suffering from hematological malignancies, and several other private companies He previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019. Mr. Lubner is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.
Dr. Neil Fleshner, M.D.
Board Member & CMO
Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center.
Dr. Fleshner is certified in both urology and epidemiology. Dr. Fleshner is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.
Dr. Joe McCann, Ph.D.
Board Member & CEO
Dr. Joe McCann, Ph.D. has served as POINT’s Chief Executive Officer since January 2020 and as a member of its board of directors since September 2019. Dr. McCann has overall responsibility for the day-to-day operations of POINT. Prior to this role, Dr. McCann was most recently the Chief Executive Officer and President of the Centre for Probe Development and Commercialization, where he led the formation and growth of the company’s contract development and manufacturing operations and the build out of multiple radiopharmaceutical manufacturing facilities. Prior to joining CPDC in 2010, Dr. McCann was a scientist in Pharmaceutical Development at GlaxoSmithKline from July 2006 until May 2010, with responsibility for developing products across all stages of clinical development. Dr. McCann has a Ph.D. in biochemistry from McMaster University.